ICAD Inc
NASDAQ:ICAD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ICAD Inc
Cash from Operating Activities
ICAD Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ICAD Inc
NASDAQ:ICAD
|
Cash from Operating Activities
-$2.7m
|
CAGR 3-Years
36%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Cash from Operating Activities
$1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
21%
|
CAGR 10-Years
33%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Cash from Operating Activities
$117m
|
CAGR 3-Years
116%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Cash from Operating Activities
$273.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Cash from Operating Activities
$127.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
13%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Cash from Operating Activities
$309.7m
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ICAD Inc
Glance View
iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 136 full-time employees. The firm operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). In the Detection segment, the Company’s solutions include advanced image analysis and workflow solutions enables healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, and a comprehensive range of artificial intelligence and computer aided detection (CAD) systems and workflow solutions for two-dimension(2D) and third dimension (3D) mammography, magnetic resonance imaging (MRI) and computed tomography (CT). In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
See Also
What is ICAD Inc's Cash from Operating Activities?
Cash from Operating Activities
-2.7m
USD
Based on the financial report for Mar 31, 2025, ICAD Inc's Cash from Operating Activities amounts to -2.7m USD.
What is ICAD Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
17%
Over the last year, the Cash from Operating Activities growth was 41%. The average annual Cash from Operating Activities growth rates for ICAD Inc have been 36% over the past three years , 17% over the past five years .
